Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Metabotropic regulation of RhoA/Rho-associated kinase by L-type Ca2+ channels.

Ureña J, López-Barneo J.

Trends Cardiovasc Med. 2012 Aug;22(6):155-60. doi: 10.1016/j.tcm.2012.07.013. Epub 2012 Aug 16. Review.

PMID:
22902183
2.

Osteoporosis--a risk factor for cardiovascular disease?

Lampropoulos CE, Papaioannou I, D'Cruz DP.

Nat Rev Rheumatol. 2012 Oct;8(10):587-98. doi: 10.1038/nrrheum.2012.120. Epub 2012 Aug 14. Review.

PMID:
22890244
3.

Association between beta-blockers and fracture risk: a Bayesian meta-analysis.

Yang S, Nguyen ND, Eisman JA, Nguyen TV.

Bone. 2012 Nov;51(5):969-74. doi: 10.1016/j.bone.2012.07.013. Epub 2012 Jul 26. Review.

PMID:
22842220
4.

A pooled analysis of vitamin D dose requirements for fracture prevention.

Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, Meyer HE, Pfeifer M, Sanders KM, Stähelin HB, Theiler R, Dawson-Hughes B.

N Engl J Med. 2012 Jul 5;367(1):40-9. doi: 10.1056/NEJMoa1109617. Erratum in: N Engl J Med. 2012 Aug 2;367(5):481. Oray, Endel J [corrected to Orav, Endel J].

5.

Bone turnover markers: use in osteoporosis.

Naylor K, Eastell R.

Nat Rev Rheumatol. 2012 Jun 5;8(7):379-89. doi: 10.1038/nrrheum.2012.86. Review.

PMID:
22664836
6.

Interactions between the immune system and bone.

D'Amelio P, Fornelli G, Roato I, Isaia GC.

World J Orthop. 2011 Mar 18;2(3):25-30. doi: 10.5312/wjo.v2.i3.25.

7.

Arterial calcification and bone physiology: role of the bone-vascular axis.

Thompson B, Towler DA.

Nat Rev Endocrinol. 2012 Sep;8(9):529-43. doi: 10.1038/nrendo.2012.36. Epub 2012 Apr 3. Review.

8.

The link between osteoporosis and cardiovascular disease.

Farhat GN, Cauley JA.

Clin Cases Miner Bone Metab. 2008 Jan;5(1):19-34.

9.

Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease.

Poletti R, Vergaro G, Zyw L, Prontera C, Passino C, Emdin M.

Int J Cardiol. 2013 Aug 10;167(3):711-5. doi: 10.1016/j.ijcard.2012.03.061. Epub 2012 Mar 28.

PMID:
22459392
10.

Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study.

Curtis JR, Ewing SK, Bauer DC, Cauley JA, Cawthon PM, Barrett-Connor E, Haney EM, Ishani A, Cremers S, Orwoll E.

J Clin Endocrinol Metab. 2012 Jun;97(6):1937-44. doi: 10.1210/jc.2011-2431. Epub 2012 Mar 22.

11.

Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation.

Fei Y, Hurley MM.

J Cell Physiol. 2012 Nov;227(11):3539-45. doi: 10.1002/jcp.24075. Review.

12.

Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism.

Rutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT.

Cardiovasc Drugs Ther. 2013 Apr;27(2):161-70. doi: 10.1007/s10557-012-6378-0. Review.

PMID:
22373564
13.

Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.

Tomaschitz A, Ritz E, Pieske B, Fahrleitner-Pammer A, Kienreich K, Horina JH, Drechsler C, März W, Ofner M, Pieber TR, Pilz S.

Cardiovasc Res. 2012 Apr 1;94(1):10-9. doi: 10.1093/cvr/cvs092. Epub 2012 Feb 13. Review.

PMID:
22334595
14.

Calcium, phosphate and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease.

Grandi NC, Brenner H, Hahmann H, Wüsten B, März W, Rothenbacher D, Breitling LP.

Heart. 2012 Jun;98(12):926-33. doi: 10.1136/heartjnl-2011-300806. Epub 2012 Feb 1.

PMID:
22301505
15.

Secondary hyperparathyroidism and mortality in hip fracture patients compared to a control group from general practice.

Madsen CM, Jørgensen HL, Lind B, Ogarrio HW, Riis T, Schwarz P, Duus BR, Lauritzen JB.

Injury. 2012 Jul;43(7):1052-7. doi: 10.1016/j.injury.2011.12.025. Epub 2012 Jan 17.

PMID:
22261083
16.

Calciotropic hormones and the risk of hip and nonspine fractures in older adults: the Health ABC Study.

Barbour KE, Houston DK, Cummings SR, Boudreau R, Prasad T, Sheu Y, Bauer DC, Tooze JA, Kritchevsky SB, Tylavsky FA, Harris TB, Cauley JA; Health ABC Study.

J Bone Miner Res. 2012 May;27(5):1177-85. doi: 10.1002/jbmr.1545.

17.

The calciotropic hormones PTH and vitamin D: from bone to blood vessels.

Cozzolino M.

J Intern Med. 2012 Jun;271(6):566-8. doi: 10.1111/j.1365-2796.2011.02501.x. Epub 2012 Jan 12. No abstract available.

18.

Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes?

Peiris AN, Youssef D, Grant WB.

South Med J. 2012 Jan;105(1):36-42. doi: 10.1097/SMJ.0b013e31823c4155. Review.

PMID:
22189665
19.

Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.

Aslan D, Andersen MD, Gede LB, de Franca TK, Jørgensen SR, Schwarz P, Jørgensen NR.

Scand J Clin Lab Invest. 2012 Feb;72(1):14-22. doi: 10.3109/00365513.2011.624631. Epub 2011 Nov 16. Review.

PMID:
22085136
20.

The cardioprotective effects of parathyroid hormone are independent of endogenous granulocyte-colony stimulating factor release.

Brunner S, Weinberger T, Huber BC, Segeth A, Zaruba MM, Theiss HD, Assmann G, Herbach N, Wanke R, Mueller-Hoecker J, Franz WM.

Cardiovasc Res. 2012 Feb 1;93(2):330-9. doi: 10.1093/cvr/cvr303. Epub 2011 Nov 10.

PMID:
22080594

Supplemental Content

Support Center